Mouse PD-L1 / B7-H1 / CD274 Protein (ECD,His Tag) 50010-M08H from Sino Biological, Inc.

Product Specs
ItemMouse PD-L1 / B7-H1 / CD274 Protein (ECD,His Tag)
CompanySino Biological, Inc.
Price $248.00Supplier Page View Company Product Page
Catalog Number50010-M08H
Conjugate/TagC-His
Purity> 98 % as determined by SDS-PAGE. ≥ 90 % as determined by SEC-HPLC
TypeRecombinant protein
Molecular WeightThe secreted recombinant mouse CD274 comprises 231 amino acids and has a predicted molecular mass of 26.3 kDa. As a result of glycosylation, it migrates as an approximately 43-55 kDa band in SDS-PAGE under reducing conditions
SpeciesMouse
Molecule NameCD274
Source/Expression SystemHEK293 Cells
NCBI Full Gene NameCD274 antigen
NCBI Gene AliasesA530045L16Rik, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1
Activity1.Loaded Recombinant Mouse PD-L1/B7-H1 Protein, His Tag (Cat. No. 50010-M08H ) on HIS1K Biosensor, can bind Recombinant Mouse PD-1 Protein, hFc Tag (Cat. No. 50124-M02H ) with an affinity constant of 0.519µM as determined in BLI assay (Sartorius Octet RED384) (Routinely tested). 2.Recombinant Mouse PD-1 Protein, hFc Tag (Cat. No. 50124-M02H) captured on Protein A chip can bind Recombinant Mouse PD-L1/B7-H1, His Tag (Cat. No. 50010-M08H) with an affinity constant of 2.489 µM as determined in an SPR assay (Biacore T200) (Routinely tested). 3.Recombinant Mouse PD-L1/B7-H1 Protein, His Tag (Cat. No. 50010-M08H) captured on CM5 chip via Anti-his antibody, can bind Recombinant Mouse PD-1 Protein, hFc Tag (Cat. No. 50124-M02H) with an affinity constant of 1.117 µM as determined in an SPR assay (Biacore T200) (Routinely tested)
FormatLyophilized from sterile PBS, pH 7.4
Size100 µg

Add to Compare List

Sino Biological, Inc.

37 Industrial Blvd

Suite B

Paoli, PA 19301

United States

Phone: 215-583-7898
Fax: 267-657-0217

Email: marketing@sinobiological.com

Company Profile

Website: sinobiological.com

(1) PD‐L1‐Binding Antigen Presenters: Redirecting Vaccine‐Induced Antibodies for Cancer ImmunotherapyAdvanced ScienceFebruary 11, 2026Huixin Gao, Lijuan Lu, Xiaoxiao Xiong, Yi Li, Donghui Hu, Duo Zhang, Zhiwei Feng, Cong Liu, Nannan Liu, Xiaoli Li, et al.Tag, SinoBiological, 10084‐H08H) protein was replaced with mouse PD‐L1 (ECD, His Tag, SinoBiological, 50010‐M08H), PBAP‐HER2 (1 µg/well and 10 µg/well) was replaced with PBAP‐gE (1 µg/well and 10 µg/well), PD‐L1 monoclonal

(2) IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapyAntibody TherapeuticsJanuary 15, 2026Dianze Chen, Zhuli Wu, Xiwen Zhao, Rupal S Bhatt, Yanan Yang, Wenqi Zhu, Huang Tang, Kaili Wang, Chunli Guo, Dandan Liu, et al.Cat#10292-H08H), Cynomolgus PD-L1 His (Sino Biological, Cat#90251-C08H), Mouse PD-L1 His (Sino Biological, Cat#50010-M08H), Rat PD-L1 His (Sino Biological, Cat#80450-R08H). IMM2510 is a bispecific antibody targeting both VEGF

(3) Rational design of NAMPT-based dual inhibitors with improved drug-like and pharmacokinetic properties for cancer treatmentEuropean journal of medicinal chemistryNovember 5, 2025Lv J, Cheng B, Song C.

(4) Cationic Peptide Conjugation Enhances Intratumoral Retention and Antitumor Efficacy of Immune Checkpoint Blockade AntibodiesBioconjugate chemistrySeptember 17, 2025Mohanty RP, Pan Y, Lewis MM, Soto MR, Maier EY, Alzhrani RF, Ghosh D.

(5) Nanofilament immunotherapy induces potent antitumor vaccine responsesJournal for immunotherapy of cancerAugust 31, 2025Neil K, Génier S, Poisson MÈ, Douchin J, Giguère H, Daniel L, Gonzalez MF, Huang S, Trinh VQ, Tai LH, et al.recombinant protein (Sino Biological, 10084-HNAH) or mouse PD-L1 recombinant protein (Sino Biological, 50010-M08H). Nanofilament variants were diluted in PBS to a standard concentration of 5×1011 particles/mL and detected

(6) A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon CancerMolecular cancer therapeuticsAugust 1, 2025Okpalanwaka IF, Daugherity EA, McCormick AL, Anderson TS, Smith SL, Lawrence C, Appiah D, Lowe DB.

(7) Discovery and Crystallography Study of Novel Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer TreatmentJournal of medicinal chemistryJune 26, 2025Yang Z, Yang P, Xu J, Yang X, Zhou J, He H, Li L, Ren Y, Chen M, Xiao Y, et al.

(8) Functional differences between rodent and human PD-1 linked to evolutionary divergenceScience immunologyJanuary 3, 2025Masubuchi T, Chen L, Marcel N, Wen GA, Caron C, Zhang J, Zhao Y, Morris GP, Chen X, Hedrick SM, et al.protein huPD-1-His (#10377-H08H), huPD-L1-His (#10084-H08H), moPD-1-His (#50124-M08H), moPDL1-His (#50010-M08H), huICAM-1 (#10346-H08H), and moICAM-1 (#50440-M08H) were purchased from SinoBiological. Recombinant

(9) Discovery of Small and Bifunctional Molecules Targeting PD-L1/CD73 for Cancer Dual ImmunotherapyJournal of medicinal chemistryJune 13, 2024Wang S, Kong Z, Shi Y, Shao C, Wang W, Su Z, Liu J, Zhou Y, Fei X, Cheng B, et al.

(10) Discovery of Highly Potent Small-Molecule PD-1/PD-L1 Inhibitors with a Novel Scaffold for Cancer ImmunotherapyJournal of medicinal chemistryMarch 14, 2024Xu Y, Du H, Guo W, Liu B, Yan W, Zhang C, Qin L, Huang J, Wang H, Wu S, et al.

(11) Intratumoral injection of IL-12-encoding mRNA targeted to CSFR1 and PD-L1 exerts potent anti-tumor effects without substantial systemic exposureMolecular therapy. Nucleic acidsSeptember 12, 2023Di Trani CA, Cirella A, Arrizabalaga L, Alvarez M, Bella Á, Fernandez-Sendin M, Russo-Cabrera JS, Gomar C, Ardaiz N, Teijeira A, et al.plate was coated with 2 μg/mL murine CSF1R (#CSR-M52E7; Acrobiosystems) or 1 μg/mL of murine PD-L1 (#50010-M08H; Sinobiological) recombinant proteins in 50 μL of PBS ON. The following day, after three washes with

(12) Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacyScience immunologyMarch 10, 2023Cohen Saban N, Yalin A, Landsberger T, Salomon R, Alva A, Feferman T, Amit I, Dahan R.

(13) Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer modelScience advancesNovember 25, 2022Liu WN, So WY, Harden SL, Fong SY, Wong MXY, Tan WWS, Tan SY, Ong JKL, Rajarethinam R, Liu M, et al.

(14) A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for cancer immunotherapyPharmacological researchAugust 1, 2022Jiao L, Dong Q, Zhai W, Zhao W, Shi P, Wu Y, Zhou X, Gao Y.

(15) Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 AgentsCancer immunology researchDecember 1, 2021Assi HH, Wong C, Tipton KA, Mei L, Wong K, Razo J, Chan C, Howng B, Sagert J, Krimm M, et al.recombinant His-tagged human or mouse PD-L1 extracellular domain (Sino Biological, catalogs #10084-H02H and #50010-M08H, respectively). Five unique scFv clones that bound human PD-L1 (hPD-L1) extracellular domain were isolated

(16) Synthesis and pharmacological evaluation of novel resorcinol biphenyl ether analogs as small molecule inhibitors of PD-1/PD-L1 with benign toxicity profiles for cancer treatmentBiochemical pharmacologyJune 1, 2021Cao H, Cheng B, Liu T, Chen J.

(17) Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer TreatmentJournal of medicinal chemistryDecember 24, 2020Cheng B, Wang W, Niu X, Ren Y, Liu T, Cao H, Wang S, Tu Y, Chen J, Liu S, et al.

(18) Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapyJournal for immunotherapy of cancerNovember 1, 2020Gao H, Wu Y, Shi J, Zhang X, Liu T, Hu B, Jia B, Wan Y, Liu Z, Wang F.performed on 96-well ELISA plates coated with 0.2 μg/well recombinant murine PD-L1 (Sino Biological, Cat: 50010-M08H, China). For the saturation binding assay, a gradient of 125I-MY1523 (1 to 200 nM) were added to the

(19) Soluble PD-L1 improved direct ARDS by reducing monocyte-derived macrophagesCell death & diseaseOctober 30, 2020Xu J, Wang J, Wang X, Tan R, Qi X, Liu Z, Qu H, Pan T, Zhan Q, Zuo Y, et al.Pseudomonas aeruginosa. After 6 h, 20 µg sPD-L1-His fused protein (PD-L1 Protein, Mouse, Recombinant (His Tag), 50010-M08H, SinoBiological) was injected into C57BL/6 mice intravenously. The mice were then sacrificed at 30 min,

(20) PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2The Journal of cell biologyJune 1, 2020Xu X, Hou B, Fulzele A, Masubuchi T, Zhao Y, Wu Z, Hu Y, Jiang Y, Ma Y, Wang H, et al.nM mouse CD86-His (Sino Biological; #50068-M08H), and either 8 nM mouse PD-L1–His (Sino Biological; #50010-M08H) or 8 nM mouse HVEM-His (BioLegend; #771304). Transduced OT-1 cells were harvested via centrifugation

Be the First to Write a Review!

Mouse PD-L1 / B7-H1 / CD274 Protein (ECD,His Tag)

Mouse PD-L1 / B7-H1 / CD274 Protein (ECD,His Tag) from Sino Biological, Inc.

Description

Sino Biological, Inc.

Citations (26)

Reviews

Mouse PD-L1 / B7-H1 / CD274 Protein (ECD,His Tag) from Sino Biological, Inc.

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map